These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17465260)

  • 21. Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder.
    Gårdmark T; Carringer M; Beckman E; Malmström PU;
    Urology; 2005 Sep; 66(3):527-30. PubMed ID: 16140071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic study to optimize the intravesical administration of gemcitabine.
    Gontero P; Cattel L; Paone TC; Milla P; Berta G; Fiorito C; Carbone F; Medana C; Tizzani A
    BJU Int; 2010 Dec; 106(11):1652-6. PubMed ID: 20590553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
    Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
    BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of intravesical gemcitabine: a preclinical study in pigs.
    Witjes JA; Vriesema JL; van der Heijden AG; Peters GJ; Schalken JA
    Eur Urol; 2003 Nov; 44(5):615-9. PubMed ID: 14572765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder.
    Maffezzini M; Campodonico F; Canepa G; Capponi G; Fontana V
    Eur Urol; 2007 Apr; 51(4):956-61. PubMed ID: 17027141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors.
    Madeb R; Golijanin D; Noyes K; Fisher S; Stephenson JJ; Long SR; Knopf J; Lyman GH; Messing EM
    Cancer; 2009 Jun; 115(12):2660-70. PubMed ID: 19455607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
    DeCastro GJ; Sui W; Pak JS; Lee SM; Holder D; Kates MM; Virk RK; Drake CG; Anderson CB; James B; Abate-Shen CT; McKiernan JM
    J Urol; 2020 Aug; 204(2):247-253. PubMed ID: 32118506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review.
    Han MA; Maisch P; Jung JH; Hwang JE; Narayan V; Cleves A; Hwang EC; Dahm P
    Investig Clin Urol; 2021 Nov; 62(6):623-630. PubMed ID: 34729962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter study on the use of gemcitabine to prevent recurrence of multiple-recurring superficial bladder tumors following intravesical antiblastic agents and/or BCG: evaluation of tolerance.
    Morabito F; Rossi R; Graziano ME; Ferrando U; Lancini V; Cretarola E; Conti G; Luporini AC; Muto G; Castelli E; D'Urso L; Razionale P; Lissoni G; Simone M; Francesca F; Sommariva M; Casu M; Hurle R
    Arch Ital Urol Androl; 2006 Mar; 78(1):1-4. PubMed ID: 16752879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study.
    Bartoletti R; Cai T; Gacci M; Giubilei G; Viggiani F; Santelli G; Repetti F; Nerozzi S; Ghezzi P; Sisani M;
    Urology; 2005 Oct; 66(4):726-31. PubMed ID: 16230125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial experience of intravesical gemcitabine for patients with high-risk superficial transitional cell carcinoma of the bladder following BCG failure.
    Allchorne P; Lamb BW; Kinsella J; Shamash J; Green JS
    Urol Nurs; 2014; 34(2):95-9. PubMed ID: 24919248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravesical gemcitabine: an update of clinical results.
    Hendricksen K; Witjes JA
    Curr Opin Urol; 2006 Sep; 16(5):361-6. PubMed ID: 16905983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Single, immediate postoperative intra-vesical instillation (SI) compared to a single preoperative intra-vesical instillation of mitomycin C in non-muscle invasive bladder cancer (NMIBC). Phase II randomized trial].
    Breton J; Bernardeau S; Vallée M; Pillot P; Lebacle C; Delpech PO; Charles T; Biscans C; Vallat A; Pfister C; Irani J
    Prog Urol; 2021 Feb; 31(2):63-70. PubMed ID: 32891506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
    Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
    J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer.
    Brocks CP; Büttner H; Böhle A
    J Urol; 2005 Sep; 174(3):1115-8. PubMed ID: 16094076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy.
    Yang Z; Fu B; Zhou L; Xu J; Hao P; Fang Z
    BMC Urol; 2019 Jul; 19(1):69. PubMed ID: 31340801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of Bacillus Calmette-Guerin refractory superficial bladder cancer: further intravesical therapy].
    Kohjimoto Y; Iba A; Shintani Y; Uekado Y; Shinka T
    Hinyokika Kiyo; 2005 Aug; 51(8):533-8. PubMed ID: 16164269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of intravesical chemoimmunotherapy with gemcitabine and Bacillus Calmette-Guérin in superficial bladder cancer: a preliminary study.
    Cho DY; Bae JH; Moon DG; Cheon J; Lee JG; Kim JJ; Yoon DK; Park HS
    J Int Med Res; 2009; 37(6):1823-30. PubMed ID: 20146880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perioperative chemotherapy: when to use it, what to use, and why.
    Johnson DC; Pruthi RS; Woods ME
    Urol Clin North Am; 2013 May; 40(2):183-95. PubMed ID: 23540777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.